High-risk multiple myeloma: how best should a newly diagnosed patient with poor-risk cytogenetics be managed?

    loading  Checking for direct PDF access through Ovid

Abstract

▪ Experts meeting at the Great Debates and Updates in Hematology conference in Chicago debated the question above. One point of view was that novel agents should be part of front-line therapy without transplantation, whereas the opposing view was that transplants should be part of the therapy.

Related Topics

    loading  Loading Related Articles